Shen Y, et al. Minimally invasive approaches for the early detection of endometrial cancer. Mol Cancer. 2023;22(1):53.

Article  PubMed  PubMed Central  Google Scholar 

Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. Obstet Gynecol Surv, 2017;72(3):169–170.

Moore KN, et al. Safety and activity of Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha–targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112.

Article  CAS  PubMed  Google Scholar 

Lewin SN, et al. Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141–9.

Article  PubMed  Google Scholar 

Cuccu I et al. Role of genomic and molecular biology in the modulation of the treatment of endometrial cancer: narrative review and perspectives. in Healthcare. 2023;11(4):571.

Mirza MR, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–58.

Article  CAS  PubMed  Google Scholar 

Mittica G, et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget. 2017;8(52):90532.

Article  PubMed  PubMed Central  Google Scholar 

Mackinnon AC Jr, et al. Pathologic, immunologic, and clinical analysis of the microsatellite instability phenotype in endometrial carcinoma. Hum Pathol. 2023;139:80–90.

Article  CAS  PubMed  Google Scholar 

Sobecki-Rausch J, Barroilhet L. Anti-programmed death-1 immunotherapy for endometrial cancer with microsatellite instability–high tumors. Curr Treat Options Oncol. 2019;20(11):83.

Article  PubMed  Google Scholar 

Hollasch M. Arn. Unpacks dostarlimab approval for patients with dMMR advanced endometrial cancer. Oncol Nurs News. 2023;12(8):451.

Berton D, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. Wolters Kluwer Health. 2021;83(12):816–13.

Oaknin A, et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res. 2023;29(22):4564–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.

Article  PubMed  Google Scholar 

Slim K, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.

Article  PubMed  Google Scholar 

Oaknin A, et al. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–72.

Article  PubMed  Google Scholar 

Oaknin A, et al. 76P analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial. Ann Oncol. 2021;32:S388–9.

Article  Google Scholar 

Coleman RL et al. Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database. American Society of Clinical Oncology. 2022;29(11):1059–65.

Oaknin A et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. J Immunother Cancer. 2022;10(1): 738–58.

Mathews C, et al. An indirect comparison of the efficacy and safety of dostarlimab and doxorubicin for the treatment of advanced and recurrent endometrial cancer. Oncologist. 2022;27(12):1058–66.

Article  PubMed  PubMed Central  Google Scholar 

André T, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open. 2023;6(11):e2341165–2341165.

Article  PubMed  PubMed Central  Google Scholar 

Goulden S et al. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer registration service in England. Int J Gynecol Cancer. 2023;33(11):1069–78.

Hill BL et al. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Int J Gynecol Cancer. 2023;33(4):271–75.

Rodrigues M, et al. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France. Bull Cancer. 2023;110(10):1041–50.

Article  PubMed  Google Scholar 

Goulden S, et al. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer registration service in England. Int J Gynecol Cancer. 2023;33(11):1715–23.

Article  PubMed  PubMed Central  Google Scholar 

Hill BL, et al. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Int J Gynecol Cancer. 2023;33(4):504–13.

Article  PubMed  PubMed Central  Google Scholar 

Powell M et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatinepaclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024;12(9):1452–59.

Madariaga A, et al. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma. Nat Commun. 2023;14(1):1452.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia C, Ring KL. The role of PD-1 checkpoint Inhibition in gynecologic malignancies. Curr Treat Options Oncol. 2018;19:1–14.

Article  Google Scholar 

Post CC, et al. PARP and PD-1/PD-L1 checkpoint Inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol/Hematol. 2020;152:102973.

Article  PubMed  Google Scholar 

Chen J, Shao R, Chen C. Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. J Solid Tumors. 2015;5(1):10–7.

Article  Google Scholar 

Goodman AM, et al. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Randrian V, Evrard C, Tougeron D. Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens, immuno-resistance and emerging therapies. Cancers. 2021;13(12):3063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Picard E, et al. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:508013.

Article  Google Scholar 

Kim ST, et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget. 2017;8(44):77415.

Article  PubMed  PubMed Central  Google Scholar 

Guan J, Li G-M. DNA mismatch repair in cancer immunotherapy. NAR cancer. 2023;5(3):zcad031.

Article  PubMed  PubMed Central  Google Scholar 

Pietrantonio F, et al. Predictive role of microsatellite instability for PD-1 Blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6(1):100036.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le DT, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schrock A, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–103.

Article  CAS  PubMed  Google Scholar 

Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396.

Article  PubMed  PubMed Central  Google Scholar 

Ghose A, et al. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci. 2021;22(18):9783.

Article  CAS  PubMed